Robust and low-cost ELISA based on IgG-Fc tagged recombinant proteins to screen for anti-SARS-CoV-2 antibodies

The development of new diagnostic assays become a priority for managing COVID-19. To this aim, we presented here an in-house ELISA based on the production of two major recombinant and high-quality antigens from SARS-CoV-2. Full-length N and S-RBD fragment proteins fused to mouse IgG2a-Fc were produc...

Descripción completa

Detalles Bibliográficos
Autores principales: Frumence, Etienne, Lebeau, Grégorie, Viranaicken, Wildriss, Dobi, Anthony, Vagner, Damien, Lalarizo Rakoto, Mahary, Sandenon Seteyen, Anne-Laure, Giry, Claude, Septembre-Malaterre, Axelle, Raffray, Loïc, Gasque, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Technical Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152238/
https://www.ncbi.nlm.nih.gov/pubmed/34051226
http://dx.doi.org/10.1016/j.jim.2021.113082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152238/
https://www.ncbi.nlm.nih.gov/pubmed/34051226
http://dx.doi.org/10.1016/j.jim.2021.113082

Ejemplares similares